Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma is a promising early stage drug development company with a focused portfolio of five novel therapeutic drug candidates for the treatment of Alzheimer's disease, a progressive neurologic disease with high unmet medical need. The company's recent achievement of 100% patient enrollment and reported positive interim results for its Phase 2 trial for IGC-AD1 demonstrate its potential for addressing key hallmarks of Alzheimer's disease and reducing agitation in patients. Despite minimal revenue, IGC Pharma's strong financial results, with revenue of $0.3 million in Q1 2026 and a net loss of $2.4 million, indicate potential for sustainable growth and support a BUY rating and price target of $5.50 based on a NPV analysis. However, risks to attainment of the price target include balance sheet/liquidity risks, competition, and regulatory approvals. With upcoming milestones in mid-2026 and a solid scientific and management team, IGC Pharma is well-positioned for success in the biotech industry.

Bears say

IGC Pharma is a biotech company focused on developing cannabinoid-based treatments for diseases and conditions, particularly Alzheimer's disease (AD) which currently has no known cure or effective treatment. With five novel drug candidates for AD and positive interim results from its Phase 2 trial for IGC-AD1, the company is well-positioned in this large market with high unmet need. However, risks such as failure in clinical trials and regulatory approvals, as well as the company's minimal revenue and balance sheet/liquidity risks, could hinder its ability to effectively commercialize and bring its products to market. This negative outlook is further reinforced by the company's financials, with Q3 revenue of only $0.4 million and a net loss of $0.7 million, and is reflected in our BUY rating and 12-month price target of $5.25 derived from a NPV analysis. Despite the potential catalysts in the form of positive trial data, we believe the risks outweigh the potential rewards in the highly competitive and rapidly evolving biotech industry.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.